Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Turing Pharmaceuticals Launches

By Drug Discovery Trends Editor | February 25, 2015

Turing Pharmaceuticals AG announced its official launch, along with news of three acquisitions for its commercial operations and development pipeline.  The company also introduced its senior management team.
 
New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options.
 
Turing’s Founder and Executive Chairman is Martin Shkreli, who has a history of success in the drug industry as founder and former CEO of Retrophin, Inc. (NASDAQ: RTRX).  At Retrophin, Mr. Shkreli led the acquisition of three key products in the six months following the company’s IPO in 2014, and significantly accelerated their commercial success.
 
In addition to Mr. Shkreli, Turing has assembled a management team comprised of senior executives with extensive experience in the drug industry, including:
 
Howard Dorfman – SVP, General Counsel; Mr. Dorfman formerly worked at Ferring Pharmaceuticals and Bayer Pharmaceuticals (US) as well as at law firm Ropes & Gray
Hass Patel, Ph.D. –VP for Chemistry, Manufacturing and Controls; Dr. Patel was previously with Pharmasset, Reliant Pharmaceuticals and GlaxoSmithKline
Nicholas Pelliccione, Ph.D. – VP, Regulatory affairs; Dr. Pelliccione was formerly with Schering-Plough, Regado Biosciences, Aeterna Zenaris and Chugai Pharma USA
Michael Harrison – Chief Financial Officer; Mr. Harrison was formerly with Retrophin
Nancy Retzlaff – Chief Commercial Officer; Ms. Retzlaff joins in early March from Mesoblast Ltd.; she was previously with Pfizer, Schering-Plough and Bayer
Megan Roberts, Ph.D. – VP and Product Leader for Vecamyl; Dr. Roberts previously worked at Genentech and BioMarin
 
“Our success in bringing to market a line of new therapeutic products very much depends on the caliber of our people,” Mr. Shkreli said.  “We’re thrilled to have assembled such a strong bench of senior talent for our launch and look forward to announcing additional key positions in due course.”
 
Simultaneous to its launch, Turing announced the acquisition of three major assets from Retrophin:  an intranasal formulation of ketamine, Syntocinon® (oxytocin nasal solution) and Vecamyl® (mecamylamine HCl tablets).
 
Turing is developing its new intranasal formulation of ketamine for a variety of psychiatric indications.  The company is making significant investments in a novel delivery mechanism and other innovations to develop ketamine for the treatment of several serious psychiatric conditions for patients who currently have limited treatment options, and expects to commence clinical trials in the coming year.
 
Turing’s plans further include a development program for Syntocinon® in addressing multiple indications across several therapeutic areas. 
 
The acquisition of Vecamyl® provides Turing with its first FDA-approved product and revenue stream, which it plans to grow through a robust clinical development and education program.
 
Turing’s strategic focus is to acquire and advance development of external compounds while also pursuing internal drug discovery through proprietary research and development to best address the needs of diverse patient populations.  Reflecting its mission to address unmet medical needs, Turing has also acquired two early-stage compounds to be developed for various orphan drug indications. The company is strongly committed to growing shareholder value.
 
“Our goal is to build a diverse portfolio and pipeline of therapies that can make a significant difference to patients,” Mr. Shkreli said. “We are creating a strong, experienced team at Turing with a solid track record of success to execute on our objectives.”
 
Source: Turing Pharmaceuticals

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE